Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis

Table 1 Area under receiver operator curve values for the prediction of treatment outcomes by the Oncostatin M

Ref.	Prognostic association	OSM cutoff	AUC [95%CI]	Sensitivity [95%CI]	Specificity [95%CI]
Bertani et al[16], 2020	Prediction of no mucosal healing after anti-TNFα therapy at week 54 by baseline serum OSM	14	0.91 [0.81, 1]	96% [82, 100]	89% [67, 97]
Bertani et al[16], 2020	Prediction of no mucosal healing after anti-TNFα therapy at week 54 by serum OSM at week 14		0.83 [0.7, 0.95]
Bertani et al[17], 2022	Prediction of no mucosal healing after anti-TNFα therapy at week 54 by baseline serum OSM	14	0.91 [0.84, 0.99]	91% [78, 97]	90% [75, 97]
Bertani et al[17], 2022	Prediction of non-response to vedolizumab therapy at week 54 by baseline serum OSM		0.56 [0.42, 0.7]
Cao et al[18], 2021	Prediction of non-response to infliximab at week 54 by baseline fecal OSM		0.638
Cao et al[18], 2021	Prediction of non-response to infliximab at week 28 by baseline fecal OSM	132	0.763	66.7%	92.5%
Ezirike Ladipo et al[21], 2021	Prediction of response to anti-TNF therapy by OSM expression in biopsies	OSM expression in pre-treatment biopsies did not predict response to anti-TNF in a pediatric population
Mateos et al[22], 2021	Prediction of response to infliximab in a calprotectin log drop measurement model	OSM was found to have predicting ability to infliximab response
Minar et al[23], 2019	Prediction of no remission after anti-TNFα therapy at week 12 by baseline serum OSM	144	0.71 [0.52, 0.89]	71%	78%
Minar et al[23], 2019	Prediction of non-response to anti-TNFα therapy at week 12 by baseline serum OSM	117	0.69 [0.5, 0.89]
Mohamed et al[24], 2022	Prediction of no remission after anti-TNFα therapy by baseline serum OSM	119	0.56 [0.31, 0.82]	66.7%	54.2%
O’connell et al[26], 2022	Prediction of response to infliximab by colonic OSM expression	No association of pretreatment colonic OSM expression with outcomes of Infliximab therapy
Zhou et al[31], 2019	Prediction of the response to PF-00547659 (anti-human mucosal addressin cell adhesion molecule-1) therapy	Baseline OSM expression/levels were unable to predict response

AUC: Area under receiver operator curve; OSM: Oncostatin M; TNF: Tumor necrosis factor.

Table 2 Area under receiver operator curve values for identifying/distinguishing treatment response by OSM

Ref.	Prognostic association	OSM cutoff	AUC [95%CI]	Sensitivity [95%CI]	Specificity [95%CI]
Cao et al[18], 2021	Identification of mucosal healing after infliximab therapy by fecal OSM		0.702
Cao et al[18], 2021	Identification of clinical remission after infliximab therapy by fecal OSM		0.674
Cao et al[19], 2022	Identification of mucosal healing after infliximab therapy by serum OSM	64.1	0.84 [0.75, 0.91]	81.8%	80.8%
Cao et al[19], 2022	Identification of clinical response to infliximab therapy by serum OSM	83	0.90 [0.8, 0.96]	86.4%	87%
Cao et al[19], 2022	Identification of clinical remission after infliximab therapy by serum OSM	98.9	0.9 [0.83, 0.95]	82.1%	86.4%
Guo et al[20], 2022	Distinction between remitters and non-remitters after 1 year of anti-TNFα therapy in CD patients by serum OSM	169	0.88 [0.79, 0.96]	76% [58, 88]	91% [80, 96]
Guo et al[20], 2022	Distinction between remitters and non-remitters after 1 year of anti-TNFα therapy in UC patients by serum OSM	234	0.94 [0.87, 1]	80% [55, 93]	96% [79, 99]
Nishioka et al[25], 2021	Distinction between anti-TNFα resistant and sensitive patients by mucosal OSM mRNA		0.83
Nishioka et al[25], 2021	Distinction between ustekinumab resistant and sensitive patients by mucosal OSM mRNA		0.77
Verstockt et al[28], 2021	Distinction between remitters and non-remitters 6 months after surgery by serum OSM		0.80 [0.68, 0.92]
Verstockt et al[28], 2021	Distinction between remitters and non-remitters after anti-TNFα therapy by serum OSM		0.52 [0.44, 0.61]
Verstockt et al[28], 2021	Distinction between remitters and non-remitters after anti-TNFα therapy by colonic OSM		0.74 [0.54, 0.94]
Verstockt et al[28], 2021	Distinction between remitters and non-remitters after vedolizumab therapy by serum OSM		0.51 [0.43, 0.59]
Verstockt et al[28], 2021	Distinction between remitters and non-remitters after vedolizumab therapy by colonic OSM		0.69 [0.53, 0.84]
West et al[29], 2017	Distinction between responders and non-responders to infliximab by mucosal OSM mRNA		0.99	100	91.7
Yokoyama et al[30], 2023	Distinction between responders and non-responders to anti-TNFα by mucosal OSM mRNA		0.94
Yokoyama et al[30], 2023	Distinction between CORT-dependent vs non-dependent remission by mucosal OSM mRNA		0.79
Zhou et al[31], 2019	Distinction between responders and non-responders to F-00547659 by change in OSM expression in inflamed tissue		0.88
Zhou et al[31], 2019	Distinction between remitters and non-remitters to F-00547659 by change in OSM expression in inflamed tissue		0.81
Zhou et al[31], 2019	Distinction between mucosal healing and no mucosal healing by F-00547659 therapy by the change in OSM expression during treatment in inflamed tissue		0.83

AUC: Area under receiver operator curve; OSM: Oncostatin M; TNF: Tumor necrosis factor.